Emcure Pharmaceuticals Ltd
NSE:EMCURE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 008
1 526.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Emcure Pharmaceuticals Ltd
Other Current Liabilities
Emcure Pharmaceuticals Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
Other Current Liabilities
₹3.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Other Current Liabilities
₹57.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Other Current Liabilities
₹25.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Other Current Liabilities
₹93.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Other Current Liabilities
₹10.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Other Current Liabilities
₹8.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Emcure Pharmaceuticals Ltd
Glance View
Emcure Pharmaceuticals Ltd. emerged as a prominent player in the Indian pharmaceutical landscape, guided by a commitment to innovation and accessibility. Founded in 1981 by Satish Mehta, the company started as a small-scale manufacturer and has since evolved into a global pharmaceutical powerhouse. Emcure thrives on a multifaceted business model that encompasses the complete pharmaceutical value chain, from research and development to manufacturing and distribution. The company's success rests on its robust portfolio of generics, branded generics, and biopharmaceuticals, which cater to diverse therapeutic areas like cardiology, oncology, gynecology, and infectious diseases. The driving force behind Emcure's financial engine is its ability to balance volume and value. Through a network of state-of-the-art facilities, Emcure sustains a strong presence both domestically and internationally, with exports spanning over 70 countries. The firm capitalizes on economies of scale by leveraging its extensive production infrastructure, allowing it to offer high-quality medications at competitive prices. Furthermore, strategic collaborations and licensing agreements empower Emcure to penetrate new markets and broaden its product offerings. By continually expanding its pipeline and embracing cutting-edge technologies, Emcure not only secures its position in the competitive pharmaceutical industry but also reinforces its mission to deliver affordable healthcare solutions globally.
See Also
What is Emcure Pharmaceuticals Ltd's Other Current Liabilities?
Other Current Liabilities
3.6B
INR
Based on the financial report for Mar 31, 2024, Emcure Pharmaceuticals Ltd's Other Current Liabilities amounts to 3.6B INR.
What is Emcure Pharmaceuticals Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 1Y
25%
Over the last year, the Other Current Liabilities growth was 25%.
You don't have any saved screeners yet
